Dr Peter Galettis

Dr Peter Galettis

Head of Clinical Pharmacology Lab

School of Medicine and Public Health

Career Summary

Biography

Dr Galettis currently holds the position of Head of the Clinical Pharmacology Laboratory and Senior Lecturer at the University of Newcastle. Previously he has held the positions of: Senior Medical Scientist at SA Pathology (2010-2015) where he was responsible for the development and implementation of new assays for the Division of Chemical Pathology; Senior Scientific Officer at the Cancer Care Centre, St George Hospital (2000-2010) where he led the Cancer Pharmacology and Therapeutics group; and Research Fellow in the Department of Pharmacology and Clinical Pharmacology, University of Auckland (1996-2000). Dr Galettis's research interests are entirely within the field of clinical pharmacology and toxicology, specialising in assay development for use in drug monitoring for the last 25 years, focussing on anticancer agents and drugs of abuse .


Qualifications

  • Doctor of Philosophy, University of Technology Sydney
  • Bachelor of Science (Honours), University of New South Wales

Keywords

  • Assay Development and Validation
  • Chromatography
  • HPLC
  • LCMS
  • Mass Spectrometry
  • Pharmacology
  • Therapeutic Drug Monitoring (TDM)
  • Toxicology

Fields of Research

Code Description Percentage
030108 Separation Science 30
110302 Clinical Chemistry (diagnostics) 10
111502 Clinical Pharmacology and Therapeutics 60

Professional Experience

UON Appointment

Title Organisation / Department
Head of Clinical Pharmacology Lab University of Newcastle
School of Medicine and Public Health
Australia
Head of Clinical Pharmacology Lab Priority Research Centre (PRC) for Healthy Lungs | The University of Newcastle
School of Medicine and Public Health
Australia
Head of Clinical Pharmacology Lab University of Newcastle
School of Medicine and Public Health
Australia

Professional appointment

Dates Title Organisation / Department
31/05/2010 - 10/04/2015 Senior Medical Scientist SA Pathology
Chemical Pathology
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
2012 Links M, Galettis P, 'One Step Closer to the Target: Intracellular Pharmacokinetics of Gemcitabine', Readings in Advanced Pharmacokinetics - Theory, Methods and Applications, INTECH, Rijeka, Croatia (2012)
DOI 10.5772/33330

Journal article (39 outputs)

Year Citation Altmetrics Link
2018 Solowij N, Galettis P, Broyd SJ, de Krey P, Martin JH, 'Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting', Drugs in R and D, 18 41-44 (2018) [C1]

© 2018, The Author(s). Background: In many health settings, administration of medicinal cannabis poses significant implementation barriers including drug storage and safety for ad... [more]

© 2018, The Author(s). Background: In many health settings, administration of medicinal cannabis poses significant implementation barriers including drug storage and safety for administering staff and surrounding patients. Different modes of administration also provide different yet potentially significant issues. One route that has become of clinical interest owing to the rapid onset of action and patient control of the inhaled amount (via breath timing and depth) is that of vaporisation of cannabinoid products. Although requiring a registered therapeutic device for administration, this is a relatively safe method of intrapulmonary administration that may be particularly useful for patients with difficulty swallowing, and for those in whom higher concentrations of cannabinoids are needed quickly. A particular concern expressed to researchers undertaking clinical trials in the hospital is that other patients, nurses, and clinical or research staff may be exposed to second-hand vapours in the course of administering vaporised products to patients. Objective: The objective of this study was to take samples from two research staff involved in administering vaporised ¿9-tetrahydrocannabinol to participants in a clinical trial, to examine and quantitate cannabinoid presence. Methods: Blood samples from two research staff were taken during the exposure period for three participants (cannabis users) over the course of approximately 2.5¿h and analysed using tandem mass spectrometry. Results: Blood samples taken over a vaporised period revealed exposure below the limit of detection for ¿9-tetrahydrocannabinol and two metabolites, using tandem mass spectrometry analytical methods. Conclusions: These results are reassuring for hospital and clinical trial practices with staff administering vaporised cannabinoid products, and helpful to ethics committees wishing to quantify risk.

DOI 10.1007/s40268-017-0225-5
Co-authors Jen Martin
2018 Lucas CJ, Galettis P, Song S, Solowij N, Reuter SE, Schneider J, Martin JH, 'Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer', Clinical Therapeutics, 40 (2018)
DOI 10.1016/j.clinthera.2017.12.008
Citations Scopus - 4Web of Science - 4
Co-authors Jennifer Schneider, Jen Martin
2018 Martin JH, Schneider J, Lucas CJ, Galettis P, 'Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?', Clinical Pharmacokinetics, 57 539-545 (2018) [C1]

© 2017, Springer International Publishing AG. Endocannabinoid pharmacology is now relatively well understood with a number of endocannabinoids and endogenous cannabinoid neurotran... [more]

© 2017, Springer International Publishing AG. Endocannabinoid pharmacology is now relatively well understood with a number of endocannabinoids and endogenous cannabinoid neurotransmitters identified and the pharmacokinetics relatively well ascertained. Further, the cannabinoid receptors are now molecularly and pharmacologically characterised and the cell processes involved in endocannabinoid transcription, synthesis, post-translational modification and protein expression are reported. Endogenous cannabinoids have been shown to have key roles in immune and pain pathways and neuro-behavioural signalling including appetite regulation. Significant recent interest has thus been shown in understanding these pathways to guide the development of agents that inhibit the natural catabolism of endogenous cannabinoids to modify pain and appetite, and to synthesise antagonists for the treatment of disease such as obesity. This research is concurrent with the renewed clinical interest in exogenous cannabinoids and their use in disease. However, the complex pharmacology and physiological effects of exogenous cannabinoids, either as individual components or in combination, as extracts or via administration of the whole plant in humans, are less well known. Yet as with all other therapeutics, including those derived from plants, knowledge of the pharmacokinetics and dynamics of the complete plant, the individual chemical molecules and their synthetic versions, including formulations and excipients is a standard part of drug development. This article covers the key pharmacological knowledge required to guide further exploration of the toxicity and efficacy of different cannabinoids and their formulations in blinded placebo-controlled studies.

DOI 10.1007/s40262-017-0599-0
Citations Scopus - 3Web of Science - 4
Co-authors Jen Martin, Jennifer Schneider
2018 Solowij N, Broyd SJ, Beale C, Prick J-A, Greenwood L-M, van Hell H, et al., 'Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial.', Cannabis Cannabinoid Res, 3 21-34 (2018) [C1]
DOI 10.1089/can.2017.0043
Co-authors Jen Martin
2018 Williams M, Martin J, Galettis P, 'A Validated Method for the Detection of Synthetic Cannabinoids in Oral Fluid.', J Anal Toxicol, (2018)
DOI 10.1093/jat/bky043
Co-authors Jen Martin
2018 Martin JH, Schneider J, Lucas CJ, Galettis P, 'Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction? (vol 57, pg 539, 2018)', CLINICAL PHARMACOKINETICS, 57 645-645 (2018)
DOI 10.1007/s40262-018-0633-x
Co-authors Jen Martin, Jennifer Schneider
2018 Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, et al., 'Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users.', Cannabis and cannabinoid research, 3 94-107 (2018) [C1]
DOI 10.1089/can.2017.0047
Co-authors Jen Martin
2018 Dryburgh LM, Bolan NS, Grof CPL, Galettis P, Schneider J, Lucas CJ, Martin JH, 'Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects.', British journal of clinical pharmacology, 84 2468-2476 (2018) [C1]
DOI 10.1111/bcp.13695
Citations Scopus - 3Web of Science - 2
Co-authors Nanthi Bolan, Chris Grof, Jennifer Schneider, Jen Martin
2018 Lucas CJ, Galettis P, Schneider J, 'The pharmacokinetics and the pharmacodynamics of cannabinoids.', British journal of clinical pharmacology, 84 2477-2482 (2018) [C1]
DOI 10.1111/bcp.13710
Citations Scopus - 4Web of Science - 1
Co-authors Jennifer Schneider
2017 Williams M, Martin J, Galettis P, 'A validated method for the detection of 32 bath salts in oral fluid', Journal of Analytical Toxicology, 41 659-669 (2017) [C1]

© The Author 2017. Published by Oxford University Press. All rights reserved. Workplace drug testing in Australia is usually adherent to one of two standards, AS/NZS 4308:2008 for... [more]

© The Author 2017. Published by Oxford University Press. All rights reserved. Workplace drug testing in Australia is usually adherent to one of two standards, AS/NZS 4308:2008 for urine or AS 4760:2006 for oral fluid. These standards prescribe the drugs tested, devices used and testing methodology followed by the testing agency. However, they are not comprehensive and for many years workers have been able to consume novel psychoactive substances to avoid detection and without consequences. Here, we present a validated method for the detection of 32 Synthetic Stimulant and Hallucogenic drugs, commonly sold as bath salts, in oral fluid. These drugs are cathinone, ephedrone, methylone, flephedrone, MDA, PMA, methedrone, TMA, MDMA, butylone, mephedrone, MDEA, MEC, pentedrone, MBDB, MTA, Alpha-PVP, MPBP, 2C-B, MDPV, DOB, 2C-T-2, TFMPP, DOET, 2C-T-7, naphyrone, MDAI, FMA, DMA, 25C-NBOMe, 25B-NBOMe and 25T4-NBOMe. Sample preparation was undertaken using a simple protein precipitation in acetonitrile. Chromatographic separation was achieved in 7.5 min on a Kinetex F5 column (50mm × 3mm × 2.6 µm) using 0.1% formic acid in water and acetonitrile as the mobile phases. The method was validated with limit of detection (1 ng/mL), limit of quantitation (2.5 ng/mL), selectivity, linearity (2.5-500 ng/mL), accuracy (85.3-108.4% of the target concentration) and precision (1.9-14%). This method was applied to 12 samples previously submitted for routine testing and two were found to contain 2-CB and DOB (5 and 4 ng/mL) and, MPBP and TFMPP (both at 4 ng/mL). This method provides for the rapid detection of a large number of compounds in oral fluid which is readily applicable to routine testing laboratories.

DOI 10.1093/jat/bkx055
Citations Scopus - 3Web of Science - 2
Co-authors Jen Martin
2016 Galettis P, Schneider J, Martin J, 'Care with overseas purchased drugs: devil is in the detail', INTERNAL MEDICINE JOURNAL, 46 1005-1006 (2016)
DOI 10.1111/imj.13184
Co-authors Jen Martin, Jennifer Schneider
2016 Schneider J, Galettis P, Williams M, Lucas C, Martin JH, 'Pill testing at music festivals: can we do more harm?', INTERNAL MEDICINE JOURNAL, 46 1249-1251 (2016)
DOI 10.1111/imj.13250
Citations Scopus - 3Web of Science - 4
Co-authors Jennifer Schneider, Jen Martin
2016 Goulooze SC, Galettis P, Boddy AV, Martin JH, 'Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours', CANCER CHEMOTHERAPY AND PHARMACOLOGY, 78 209-216 (2016) [C1]
DOI 10.1007/s00280-016-3071-1
Citations Web of Science - 5
Co-authors Jen Martin
2013 Ehteda A, Galettis P, Pillai K, Morris DL, 'Combination of Albendazole and 2-Methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice', BMC CANCER, 13 (2013)
DOI 10.1186/1471-2407-13-86
Citations Scopus - 15Web of Science - 15
2012 Ehteda A, Galettis P, Chu SWL, Pillaii K, Morris DL, 'Complexation of Albendazole with Hydroxypropyl-beta-Cyclodextrin Significantly Improves its Pharmacokinetic Profile, Cell Cytotoxicity and Antitumor Efficacy in Nude Mice', ANTICANCER RESEARCH, 32 3659-3666 (2012)
Citations Scopus - 12Web of Science - 11
2011 Luk PP, Galettis P, Links M, 'ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478', Lung Cancer, 73 274-282 (2011) [C1]
DOI 10.1016/j.lungcan.2010.12.016
Citations Scopus - 5Web of Science - 4
2011 Manners S, Galettis P, Souza PD, 'Conditions causing gemcitabine crystallization', Journal of Oncology Pharmacy Practice, 17 395-399 (2011)
DOI 10.1177/1078155210385033
Citations Scopus - 1
2011 Mitchell PL, Broad A, Rosenthal MA, Galettis P, Abraham R, Burns I, et al., 'Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer', Asia-Pacific Journal of Clinical Oncology, 7 376-384 (2011)
DOI 10.1111/j.1743-7563.2011.01390.x
Citations Scopus - 1
2011 Metharom E, Galettis P, Manners S, Jelinek M, Liauw W, De Souza PL, et al., 'The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C', Asia-Pacific Journal of Clinical Oncology, 7 65-74 (2011)
DOI 10.1111/j.1743-7563.2010.01354.x
Citations Scopus - 6Web of Science - 6
2010 Pourgholami MH, Cai ZY, Chu SWL, Galettis P, Morris DL, 'The Influence of Ovarian Cancer Induced Peritoneal Carcinomatosis on the Pharmacokinetics of Albendazole in Nude Mice', ANTICANCER RESEARCH, 30 423-428 (2010)
Citations Scopus - 5Web of Science - 4
2010 Metharom E, Galettis P, Manners S, Links M, 'Modulation of Gemcitabine Accumulation by DNA-Damaging Agents: Mechanisms and Specificity in an In Vitro Model', ANTICANCER RESEARCH, 30 3669-3673 (2010)
Citations Scopus - 1Web of Science - 1
2010 Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, et al., 'Emerging roles for phospholipase A(2) enzymes in cancer', BIOCHIMIE, 92 601-610 (2010)
DOI 10.1016/j.biochi.2010.03.019
Citations Scopus - 83Web of Science - 81
2010 Pourgholami MH, Szwajcer M, Chin M, Liauw W, Seef J, Galettis P, et al., 'Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer', CANCER CHEMOTHERAPY AND PHARMACOLOGY, 65 597-605 (2010)
DOI 10.1007/s00280-009-1157-8
Citations Scopus - 31Web of Science - 29
2009 McPherson RAC, Galettis PT, de Souza PL, 'Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells', BRITISH JOURNAL OF CANCER, 100 649-655 (2009)
DOI 10.1038/sj.bjc.6604920
Citations Scopus - 8Web of Science - 7
2008 Liu JJ, Galettis P, Farr A, Maharaj L, Samarasinha H, McGechan AC, et al., 'In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake', JOURNAL OF INORGANIC BIOCHEMISTRY, 102 303-310 (2008)
DOI 10.1016/j.jinorgbio.2007.09.003
Citations Scopus - 140Web of Science - 133
2008 Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ, 'Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 65 326-333 (2008)
DOI 10.1111/j.1365-2125.2007.03040.x
Citations Scopus - 18Web of Science - 16
2007 Cai Z-Y, Galettis P, Lu Y, Morris DL, Pourgholami MH, 'Pharmacokinetics of albendazole in New Zealand white rabbits: Oral versus intraperitoneal administration', ANTICANCER RESEARCH, 27 417-422 (2007)
Citations Scopus - 12Web of Science - 11
2007 Grimison P, Galettis P, Manners S, Jelinek M, Metharom E, de Souza PL, et al., 'Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: Evidence of auto-induction of gemcitabine accumulation', JOURNAL OF CLINICAL ONCOLOGY, 25 5704-5709 (2007)
DOI 10.1200/JCO.2007.10.7078
Citations Scopus - 19Web of Science - 16
2006 Gan HK, Mitchell PL, Galettis P, Davis ID, Cebon J, de Souza P, Links M, 'A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors', CANCER CHEMOTHERAPY AND PHARMACOLOGY, 58 157-164 (2006)
DOI 10.1007/s00280-005-0152-y
Citations Scopus - 6Web of Science - 7
2000 Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC, 'Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs', BRITISH JOURNAL OF CANCER, 82 966-972 (2000)
DOI 10.1054/bjoc.1999.1026
Citations Scopus - 126Web of Science - 122
2000 McKeage MJ, Berners-Price SJ, Galettis P, Bowen RJ, Brouwer W, Ding L, et al., 'Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes', CANCER CHEMOTHERAPY AND PHARMACOLOGY, 46 343-350 (2000)
DOI 10.1007/s002800000166
Citations Scopus - 144Web of Science - 128
1999 Berners-Price SJ, Bowen RJ, Galettis P, Healy PC, McKeage MJ, 'Structural and solution chemistry of gold(I) and silver(I) complexes of bidentate pyridyl phosphines: selective antitumour agents', COORDINATION CHEMISTRY REVIEWS, 185-6 823-836 (1999)
DOI 10.1016/S0010-8545(99)00039-9
Citations Scopus - 117Web of Science - 113
1999 Galettis P, Carr JL, Paxton JW, McKeage MJ, 'Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation', JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 14 953-956 (1999)
DOI 10.1039/a900199i
Citations Scopus - 28Web of Science - 26
1999 Links M, Watson S, Lethlean K, Aherne W, Kirsten F, Clarke S, et al., 'Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin', CANCER INVESTIGATION, 17 479-485 (1999)
DOI 10.3109/07357909909032857
Citations Scopus - 1
1999 McKeage MJ, Haddad GG, Ding L, Galettis P, Screnci D, Zhuang L, Baguley BC, 'Neuroprotective interactions in rats between paclitaxel and cisplatin', ONCOLOGY RESEARCH, 11 287-293 (1999)
Citations Scopus - 13Web of Science - 9
1998 Screnci D, Galettis P, Baguley BC, McKeage MJ, 'Optimization of an ICP-MS assay for the detection of trace levels of platinum in peripheral nerves', ATOMIC SPECTROSCOPY, 19 172-175 (1998)
Citations Scopus - 15Web of Science - 16
1997 Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ, 'Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin', BRITISH JOURNAL OF CANCER, 76 502-510 (1997)
DOI 10.1038/bjc.1997.416
Citations Scopus - 29Web of Science - 29
1994 GALETTIS P, BOUTAGY J, MA DDF, 'DAUNORUBICIN PHARMACOKINETICS AND THE CORRELATION WITH P-GLYCOPROTEIN AND RESPONSE IN PATIENTS WITH ACUTE-LEUKEMIA', BRITISH JOURNAL OF CANCER, 70 324-329 (1994)
DOI 10.1038/bjc.1994.301
Citations Scopus - 25Web of Science - 27
1990 GALETTIS P, NORTON RS, 'BIOCHEMICAL AND PHARMACOLOGICAL STUDIES OF THE MECHANISM OF ACTION OF TENEBROSIN-C, A CARDIAC STIMULATORY AND HEMOLYTIC PROTEIN FROM THE SEA-ANEMONE, ACTINIA-TENEBROSA', TOXICON, 28 695-706 (1990)
DOI 10.1016/0041-0101(90)90258-9
Citations Scopus - 28Web of Science - 22
Show 36 more journal articles

Conference (7 outputs)

Year Citation Altmetrics Link
2018 Radovanovic M, Schneider J, Ackland S, Norris R, Martin J, Galettis P, 'Microsampling as an Alternative CollectionMethod to Venous Blood to Quantify Capecitabine and its Metabolites by LC-MS/MS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Jennifer Schneider
2017 Garg M, Schneider J, Ackland S, Martin J, Galettis P, 'A Simple, Sensitive and Rapid LC-MS/MS Method for the Simultaneous Measurement of Anthracyclines, Cyclophosphamide and Taxanes in Breast Cancer Patients Samples', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Co-authors Jarad Martin, Jennifer Schneider, Stephen Ackland
2017 Martin J, Lucas CJ, Reuter SE, Galettis P, 'Cannabinoid Toxicity Post Therapeutic Intraperitoneal Injection', Prague, Czech Republic (2017)
Co-authors Jen Martin
2017 Harris B, Viet P, Perera V, Szyc A, Galettis P, Beale P, et al., 'Systemic Inflammation Alters Carboplatin Pharmacokinetics Explaining Poor Survival in Advanced Lung Cancer Patients', JOURNAL OF THORACIC ONCOLOGY (2017)
2016 Galettis P, 'DEVELOPMENT OF A SIMPLE LCMSMS METHOD FOR THC AND METABOLITES IN PLASMA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Citations Web of Science - 2
2015 Garg M, Galettis P, Goulooze S, Clingan P, Ranson M, Sakoff J, et al., 'THERAPEUTIC DRUG MONITORING FOR CANCER PATIENTS RECEIVING CHEMOTHERAPY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Stephen Ackland, Jennette Sakoff, Jen Martin
2009 Metharom E, Galettis P, Manners S, Jelinek M, de Souza P, Links M, 'Cytidine Deaminase c.79A \ C Polymorphism Affected Optimal Dose Delivery of Gemcitabine', DRUG METABOLISM REVIEWS, Bangkok, THAILAND (2009)
Show 4 more conferences
Edit

Grants and Funding

Summary

Number of grants 9
Total funding $6,133,065

Click on a grant title below to expand the full details for that specific grant.


20184 grants / $5,945,705

The NSW Clinical Cannabis Medicines Program$3,943,754

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Professor Jennifer Martin, Associate Professor Jenny Schneider, Doctor Peter Galettis, Doctor Catherine Lucas
Scheme Research Funds
Role Investigator
Funding Start 2018
Funding Finish 2020
GNo G1701636
Type Of Funding C2210 - Aust StateTerritoryLocal - Own Purpose
Category 2210
UON Y

PREDICT — Pathway of Research to Evaluation of Dose-Individualised Cancer Therapy: Development of a national individualised cancer dosing program to both generate evidence and implement existing evi$1,961,951

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Professor Jennifer Martin, Conjoint Professor Stephen Ackland, Professor Howard Gurney, Professor Paul de Souza, Professor Michael Michael, Professor Alan Boddy, Professor Paul Scuffham, Dr Stephanie Reuter Lange, Doctor Peter Galettis, Boddy, Alan, Gurney, Howard, Michael, Michael, Reuter Lange, Stephanie, Scuffham, Paul
Scheme Pathways to a Cancer-Free Future
Role Investigator
Funding Start 2018
Funding Finish 2022
GNo G1701238
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

A simple fingerprick and blood test to optimize chemotherapy dosing in oesophageal cancer$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Jenny Schneider, Doctor Peter Galettis, Professor Jennifer Martin, Conjoint Professor Stephen Ackland, Doctor Catherine Lucas
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800190
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Standard doses of anti-PD-1 immunotherapy for metastatic melanoma may not be sufficient for all patients and may influence patient response to therapy$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Nikola Bowden, Doctor Moira Graves, Dr Andre van der Westhuizen, Mr Ricardo Vilain, Doctor Peter Galettis
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1801346
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20171 grants / $25,000

Defining and predicting clinical toxicity in GBM patients undergoing temozolomide-radiation treatment: A multivariate study$25,000

Funding body: Mark Hughes Foundation

Funding body Mark Hughes Foundation
Project Team Doctor James Lynam, Doctor Jennette Sakoff, Professor Jennifer Martin, Doctor Lisa Lincz, Doctor Michael Fay, Doctor Peter Galettis
Scheme Research Funding
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700586
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20163 grants / $95,709

Evaluation of cannabinoids in cancer-related anorexia cachexia syndrome: A Phase III double blind Randomised Controlled Trial$48,750

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Professor Jennifer Martin, Doctor Peter Galettis, Associate Professor Meera Agar
Scheme Research Funds
Role Investigator
Funding Start 2016
Funding Finish 2019
GNo G1600542
Type Of Funding C2210 - Aust StateTerritoryLocal - Own Purpose
Category 2210
UON Y

Analysis of Cannabinoids$25,000

Funding body: University of Wollongong

Funding body University of Wollongong
Project Team Professor Jennifer Martin, Doctor Peter Galettis
Scheme Research Consultancy
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1601398
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

Bioimpedence Scales$21,959

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Jennifer Martin, Doctor Peter Galettis, Conjoint Professor Stephen Ackland
Scheme Equipment Grant
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1600825
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20141 grants / $66,651

Effect of obesity on exposure to breast cancer chemotherapy: still a need to 'cap' the dose?$66,651

Funding body: University of Queensland

Funding body University of Queensland
Project Team Professor Jennifer Martin, Doctor Peter Galettis
Scheme Research Project
Role Investigator
Funding Start 2014
Funding Finish 2016
GNo G1601146
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y
Edit

Research Supervision

Number of supervisions

Completed5
Current3

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2018 PhD Cannabinoids and Acute Pain Post Surgery PhD (Clinical Pharm), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 Masters Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults M Philosophy (Medicine), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2015 PhD Development of Methods for the Detection of Novel Psychoactive Substances in Oral Fluid PhD (Clinical Pharm), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2012 PhD Mechanisms of the anti-angiogenic effects of microtubule binding anti-cancer drugs Pharmacology, University of New South Wales Principal Supervisor
2011 PhD Improving the anti-tumour efficacy of Albendazole Surgery, University of New South Wales Co-Supervisor
2010 PhD Gemcitabine pharmacogenetics and mechanisms involved in synergistic interaction of gemcitabine in combination with platinum drugs Pharmacology, University of New South Wales Principal Supervisor
2010 PhD The influence of the EGFR pathway in modulating the efficacy of gemcitabine Internal Medicine, University of New South Wales Co-Supervisor
2007 PhD Study of albendazole in peritoneal carcinomatosis Surgery, University of New South Wales Co-Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 42
New Zealand 9
United States 2
United Kingdom 1
Netherlands 1
Edit

Dr Peter Galettis

Position

Head of Clinical Pharmacology Lab
Clinical Pharmacology
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email peter.galettis@newcastle.edu.au
Phone (02) 4913 8790

Office

Room 3108
Building HMRI
Location John Hunter Site

,
Edit